View Older Stories View More Recent Stories

Oct 25, 2018 06:45AM Merck Announces Third-Quarter 2018 Financial Results
Oct 22, 2018 10:31AM Merck (MRK) Says KEYTRUDA Significantly Improved OS Compared to Standard of Care in Patients with Recurrent or Metastatic Head and Neck Cancer
Oct 22, 2018 10:30AM Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with
Oct 22, 2018 06:48AM Merck (MRK) Says EMA Adopts Positive Opinion for its KEYTRUDA as Adjuvant Therapy in Melanoma
Oct 22, 2018 06:45AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Melanoma
Oct 22, 2018 06:12AM Merck (MRK) Presents Early Data for Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
Oct 22, 2018 05:47AM AstraZeneca (AZN), Merck (MRK) Report Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70%
Oct 21, 2018 10:30AM SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian C
Oct 20, 2018 09:00AM First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
Oct 20, 2018 03:15AM Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
Oct 18, 2018 07:01AM Merck (MRK) Reports Significant Improved OS & PFS Data from Pivotal Phase 3 KEYNOTE-426 Trial Investigating KEYTRUDA (pembrolizumab) in Combination with Pfizer’s (PFE) Inlyta (axitinib)
Oct 18, 2018 06:57AM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advan
Oct 17, 2018 06:45AM Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer
Oct 16, 2018 06:32AM AstraZeneca (AZN) and Merck (MRK) Announce FDA Grants LYNPARZA Orphan Drug Designation for Pancreatic Cancer
Oct 16, 2018 06:30AM U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer
Oct 10, 2018 06:45AM Merck to Hold Third-Quarter 2018 Sales and Earnings Conference Call on October 25
Oct 9, 2018 06:30AM Merck’s Broad Oncology Pipeline to Be Highlighted at ESMO 2018 Congress
Oct 4, 2018 08:00AM MilliporeSigma Opens M Lab™ Collaboration Center in São Paulo, Brazil
Oct 4, 2018 06:45AM Merck (MRK) Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO to Treat HIV
Oct 4, 2018 06:45AM Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Anti
Oct 4, 2018 06:45AM Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Pat
Oct 1, 2018 08:00AM Merck Announces “Safer Childbirth Cities” Initiative, Issues Call to Action to Reverse the Rise in U.S. Maternal Deaths
Sep 26, 2018 06:45AM Merck (MRK) Rescinds Mandatory CEO Retirement Policy
Sep 26, 2018 06:45AM Merck Board Rescinds Mandatory CEO Retirement Policy
Sep 20, 2018 04:31PM Merck (MRK) Receives Positive CHMP Opinion for DELSTRIGO and PIFELTRO in EU for Treatment of HIV-1 Infection
Sep 20, 2018 04:30PM Merck Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO™ (doravirine) in the European Union for the Treatment of HIV-1 Infection
Sep 20, 2018 08:00AM Merck Publishes Corporate Responsibility Report
Sep 12, 2018 06:48AM Merck (MRK) Granted FDA Priority Review for Application of KEYTRUDA (pembrolizumab) Monotherapy
Sep 12, 2018 06:45AM FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose T
Sep 11, 2018 08:28AM BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Sep 11, 2018 06:46AM Merck's (MRK) ZERBAXA Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with HABP or VABP
Sep 11, 2018 06:45AM Merck’s ZERBAXA® (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or
Sep 10, 2018 06:47AM Merck (MRK) Announces EC Approves its KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy for Treatment of Patients with Metastatic Nonsquamous NSCLC
Sep 10, 2018 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, w
Sep 7, 2018 08:00AM Merck to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
Sep 6, 2018 06:30AM Data from Merck’s Leading Lung Cancer Research Program with KEYTRUDA® (pembrolizumab) to be Presented at IASLC 19th World Conference on Lung Cancer
Sep 5, 2018 06:48AM Merck (MRK), Eisai Co. Report China NMPA Approval of LENVIMA (lenvatinib) for Treatment of Unresectable Hepatocellular Carcinoma
Sep 5, 2018 06:45AM Eisai and Merck Announce China National Medical Products Administration (NMPA) Approval of LENVIMA® (lenvatinib) for Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Sep 4, 2018 06:47AM Merck (MRK) KEYTRUDA Granted FDA Priority Review for Rare Form of Skin Cancer
Sep 4, 2018 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Merkel Cell Carcinoma, a Rare Form of Skin Cancer
Aug 30, 2018 04:13PM Merck (MRK) Announces FDA Approval of Two new HIV-1 Medicines
Aug 30, 2018 04:05PM FDA Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI,
Aug 23, 2018 06:35AM Merck (MRK), Eisai Announce EC Grants Marketing Authorization for LENVIMA as First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma
Aug 23, 2018 06:30AM Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA® (lenvatinib) as First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma
Aug 20, 2018 04:06PM Merck (MRK) Reports Expanded Label for KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy
Aug 20, 2018 04:05PM FDA Approves Expanded Label for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy for First-Line Treatment of Patients with Metastatic Nonsquamou
Aug 17, 2018 08:00AM Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Aug 17, 2018 08:00AM Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management
Aug 16, 2018 04:18PM Merck (MRK), Eisai Inc. Report FDA Approval of LENVIMA (lenvatinib) Capsules for First-line Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Aug 16, 2018 04:11PM Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
View More Recent Stories View Older Stories